Sirna Therapeutics to Present at Two Upcoming Conferences
August 31 2006 - 5:30PM
PR Newswire (US)
SAN FRANCISCO, Aug. 31 /PRNewswire-FirstCall/ -- Sirna
Therapeutics, Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi
therapeutics company, announced today that management is scheduled
to give a company presentation at two upcoming conferences. *
BioCentury/Thomson Financial 13th Annual Newsmakers in the Biotech
Industry Conference on Thursday, September 7, 2006 at 9:30 a.m. EDT
at the Millennium Broadway Hotel and Conference Center in New York,
NY. For more information on this conference please log onto
http://www.biocentury.com/html/conferences/nm/2006/index.htm *
Thomas Weisel Partners Healthcare Conference on Thursday, September
7, 2006 at 4:25 p.m. EDT at the Four Seasons Hotel in Boston, MA.
For more information on this conference please log onto
http://www.tweisel.com/twpds?__fwdtourl__=/user/login1.jsp About
Sirna Therapeutics Sirna Therapeutics is a clinical-stage
biotechnology company developing RNAi-based therapies for serious
diseases and conditions, including age-related macular degeneration
(AMD), hepatitis C, dermatology, asthma, respiratory syncytial
virus (RSV) and Huntington's disease. Sirna Therapeutics completed
its Phase 1 clinical trial for Sirna-027 in AMD in 2005 and with
its strategic partner, Allergan, Inc., will move Sirna-027 into
Phase 2 clinical trials in the second half of 2006. Sirna has
selected a clinical candidate for hepatitis C virus, Sirna-034,
which the Company plans to bring into Phase 1 clinical trials by
the end of 2006. Sirna has established an exclusive multi-year
strategic alliance with GlaxoSmithKline for the development of
siRNA compounds for the treatment of respiratory diseases. Sirna
has a leading intellectual property portfolio in RNAi covering over
250 mammalian gene and viral targets and over 200 issued or pending
patents covering other major aspects of RNAi technology, including
the microRNA technology. More information on Sirna Therapeutics is
available on the Company's web site at http://www.sirna.com/ . Safe
Harbor Statement Statements in this press release which are not
strictly historical are "forward-looking" statements which should
be considered as subject to many risks and uncertainties. For
example, most drug candidates do not become approved drugs. The
development of Sirna-027 and Sirna-034 as well as Sirna's other
programs are still at a relatively early stage. All of these
programs, and Sirna's ability to obtain milestone and royalty
payments for them, are subject to significant risks and unknowns,
are highly contingent upon future successes, and require
significant funding. In addition, patent applications may not
result in issued patents, and issued patents may not be enforceable
or could be invalidated. Other risks and uncertainties include,
among others, Sirna's early stage of development, Sirna's history
and expectation of losses and need to raise capital, Sirna's need
to obtain clinical validation and regulatory approval for
Sirna-027, Sirna-034 and Sirna's other product candidates, any of
which could have negative results, Sirna's need to engage
collaborators, Sirna's need to obtain and protect intellectual
property, and the risk of third-party patent infringement claims.
These and additional risk factors are identified in Sirna's
Securities and Exchange Commission filings, including Forms 10-K
and 10-Q and in other SEC filings. Sirna undertakes no obligation
to revise or update any forward-looking statements in order to
reflect events or circumstances that may arise after the date of
this release. Contacts: Stephan Herrera Executive Director of
Investor Relations Sirna Therapeutics, Inc. 415-512-7200; Stephanie
Carrington The Ruth Group (646) 536-7017; DATASOURCE: Sirna
Therapeutics, Inc. CONTACT: Stephan Herrera, Executive Director of
Investor Relations of Sirna Therapeutics, Inc., +1-415-512-7200, ;
or Stephanie Carrington of The Ruth Group, +1-646-536-7017, , for
Sirna Therapeutics, Inc. Web site: http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Apr 2024 to May 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From May 2023 to May 2024